

James R. Condo (#005867)
Amanda C. Sheridan (#027360)
SNELL & WILMER L.L.P.
One Arizona Center
400 E. Van Buren, Suite 1900
Phoenix, AZ 85004-2204
Telephone: (602) 382-6000
jcondo@swlaw.com
asheridan@swlaw.com

Richard B. North, Jr. (admitted *pro hac vice*)
Georgia Bar No. 545599
Matthew B. Lerner (admitted *pro hac vice*)
Georgia Bar No. 446986
NELSON MULLINS RILEY & SCARBOROUGH LLP
Atlantic Station
201 17th Street, NW, Suite 1700
Atlanta, GA 30363
Telephone: (404) 322-6000
richard.north@nelsonmullins.com
matthew.lerner@nelsonmullins.com

Attorneys for Defendants
C. R. Bard, Inc. and
Bard Peripheral Vascular, Inc.

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF ARIZONA

IN RE: Bard IVC Filters Products Liability
Litigation

No. 2:15-MD-02641-DGC

**DEFENDANTS' RESPONSE IN
OPPOSITION TO PLAINTIFF'S
MOTION *IN LIMINE* NO. 9 TO
EXCLUDE EVIDENCE OF TRADE
ASSOCIATIONS, SOCIETIES, OR
ORGANIZATIONS**

(Assigned to the Honorable David G.
Campbell)

Defendants C. R. Bard, Inc. and Bard Peripheral Vascular, Inc. (collectively “Bard”) submit this response in opposition to Plaintiff’s Motion *in Limine* No. 9 and respectfully show the Court as follows:

ARGUMENT AND CITATION OF AUTHORITY

A. Such Material Is Admissible as Non-Hearsay, an Exception to Hearsay, and as a Basis of Opinions Offered by Bard’s Medical Experts.

The Plaintiff argues that “medical societies’ statements constitute inadmissible hearsay . . . to the extent that they are offered for the truth of the matter asserted.” (Pl.’s Mot. at 2.) Bard need not be offering such statements for the truth of the matter asserted, however. Therefore, the Plaintiff’s argument fails.

Under Georgia’s risk-utility test for design defect, juries may consider, among other factors, the likelihood of the danger, the user’s knowledge of the product, publicity surrounding the danger, common knowledge, the state of the art at the time the product is manufactured, and proof of compliance with industry-wide practices. *See Banks v. ICI Americas, Inc.*, 450 S.E.2d 671, 675 n.6 (Ga. 1994). Statements of medical societies, about IVC filters and reported complications with IVC filters, regardless of truth of those statements, are relevant to the jury’s consideration of these risk-utility factors. For example, the *Quality Improvement Guidelines for Percutaneous Permanent Inferior Vena Cava Filter Placement for the Prevention of Pulmonary Embolism*, published periodically since 2001 by the Society of Interventional Radiology (“SIR”) addresses reported rates of IVC filter complications generally seen by physicians as reported in the medical literature. The SIR Guidelines discuss the complications of fracture, tilt, migration, and penetration of the IVC, citing to articles in the medical literature. The jury should be able to consider this evidence when weighing whether these complications amounted to “common knowledge,” and when assessing “publicity surrounding the danger” of these complications, for instance.

Likewise, such statements that were provided to the medical community (whether true or not), are relevant to the jury’s consideration of whether Bard’s warnings were

adequate and whether any such failure caused her physician to use the G2® Filter instead of a different filter. *See, e.g., Thornton v. E.I. Du Pont de Nemours & Co.*, 22 F.3d 284, 289 (11th Cir. 1994) (discussing duty to warn under Georgia law of “nonobvious” foreseeable dangers and the need to provide “an adequate warning”).

Even if statements by medical societies are offered for the truth of the matter asserted, they reflect statements in learned treatises, periodicals, or pamphlets under Federal Rule of Evidence 803(18), and therefore are admissible as an exception to the hearsay rule. And regardless of hearsay, Bard’s medical experts have relied on, and properly disclosed their reliance on, the SIR Guidelines in forming their opinions, and therefore Bard’s experts’ opinions based on the SIR Guidelines are admissible under Rule 703, and were unchallenged by the Plaintiff in any *Daubert* motions.

Finally, counsel for the Plaintiff may cross examine witnesses who address the SIR Guidelines and any other associations, trade groups, organizations, or societies of physicians; Plaintiff may also call her own witnesses, and argue to the jury about the relative significance of such statements and non-statements.¹

Accordingly, what medical societies, like the SIR, say or do not say about risks of IVC filters generally and/or of Bard’s G2® Filter specifically are relevant to the jury’s consideration of the Plaintiff’s design and warning claims and should be admissible on numerous grounds.

B. *Daubert* and Rule 703 Are Inapplicable.

The Plaintiff’s argument that Bard will attempt to offer expert opinions through fact witnesses is inaccurate. The SIR Guidelines, however, were discussed routinely among Bard employees and with the FDA. These fact witnesses should be permitted to testify and be cross examined about things they said and actions they took during the

¹ Plaintiff incorrectly argues that absence of a statement from medical societies constitutes hearsay. *See e.g., Llamas v. Seibel*, No. 16-CV-05812-WHO, 2017 WL 3782175, at *8 (N.D. Cal. Aug. 31, 2017) (“Testimony regarding the *absence* of a statement is not hearsay.”) (emphasis original); *see also, e.g., Fed. R. Evid.* 801 (“‘Statement’ means a person’s oral assertion, written assertion, or nonverbal conduct, if the person intended it as an assertion.”).

1 course of their employment concerning the SIR Guidelines. Moreover, the Plaintiff has
 2 developed extensive expert opinion to rebut any testimony that counsel purports to be
 3 concerned about. (*See e.g.*, Expert Report of Drs. Kinney, Roberts, and Kalva, Doc. 7300
 4 Exhibit G, at pp. 86-104.) As such, *Daubert* and Rule 703 are inapplicable.

5 **C. Any Danger of Prejudice or Waste of Time Is Not Substantially Outweighed**
 6 **by the Probative Value.**

7 The foundation for the Plaintiff's argument is that, in other cases, Bard used the
 8 SIR Guidelines to establish acceptable safety thresholds and complication rates. But the
 9 Plaintiff's claim is inaccurate, and the Plaintiff has cited nothing to the contrary. The
 10 Plaintiff also claims that the SIR Guidelines are irrelevant because they concern only
 11 permanent filters. But the G2® Filter at issue in Ms. Booker's case was first cleared as a
 12 permanent filter before receiving clearance as a retrievable filter. And although the 2001
 13 and 2003 SIR Guidelines concern permanent filters, the 2011, 2016, and 2017 SIR
 14 Guidelines concern both permanent and retrievable filters. Finally, the Plaintiff argues
 15 that the SIR Guidelines will result in "mini-trials," but efficient management of the
 16 evidence and adherence to the Court's time limits will avoid this issue. As discussed
 17 above, the SIR Guidelines are relevant to the jury's consideration of Georgia's risk-utility
 18 test and the Plaintiff's failure-to-warn claim, and they are factually relevant to what Bard
 19 did and said regarding its G2® Filter. Indeed, excluding the SIR Guidelines would risk
 20 confusing the jury because many relevant events in this case refer to or relate to the SIR
 21 Guidelines, and discussion of the SIR Guidelines therefore will provide the jury with
 22 necessary context. In short, the Plaintiffs have not demonstrated at this *in limine* stage
 23 that the probative value of the SIR Guidelines, and any other evidence of trade
 24 associations, societies, or organizations, is "substantially outweighed" by the danger of
 25 unfair prejudice and "unnecessary mini trials."

26 **CONCLUSION**

27 For these reasons, Bard respectfully requests that this Court deny the Plaintiff's
 28 Motion *in Limine* No. 9.

1 RESPECTFULLY SUBMITTED this 9th day of February, 2018.

2 s/ Richard B. North, Jr.
3 Richard B. North, Jr.
4 Georgia Bar No. 545599
5 Matthew B. Lerner
6 Georgia Bar No. 446986
7 NELSON MULLINS RILEY & SCARBOROUGH, LLP
8 Atlantic Station
9 201 17th Street, NW / Suite 1700
10 Atlanta, GA 30363
11 PH: (404) 322-6000
12 FX: (404) 322-6050
13 richard.north@nelsonmullins.com
14 matthew.lerner@nelsonmullins.com

15 James R. Condo (#005867)
16 Amanda Sheridan (#027360)
17 SNELL & WILMER L.L.P.
18 One Arizona Center
19 400 E. Van Buren
20 Phoenix, AZ 85004-2204
21 PH: (602) 382-6000
22 jcondo@swlaw.com
23 asheridan@swlaw.com

24 **Attorneys for Defendants C. R. Bard, Inc. and**
25 **Bard Peripheral Vascular, Inc.**
26
27
28

CERTIFICATE OF SERVICE

I hereby certify that on this 9th day of February, 2018, the foregoing was electronically filed with the Clerk of Court using the CM/ECF system which will automatically send email notification of such filing to all attorneys of record.

s/Richard B. North, Jr.
Richard B. North, Jr.

Nelson Mullins Riley & Scarborough

L.L.P.
201 17th Street NW, Suite 1700
Atlanta, GA 30363
(404) 322-6000